




NASDAQ: LFWD

Platform to Restore Motion, Dignity, and Independence

Transforming Rehabilitation. Changing Lives.

Investor Presentation · September 2026



Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical fact are forward-looking statements. Forward-looking statements may include projections regarding Lifeward’s future performance and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek,” and similar terms or phrases.

Forward-looking statements contained in this presentation include, but are not limited to, statements regarding our expectations relating to the timing of FDA clearance and commercial launch of our current and pipeline products, including the AlterG StrideSense platform, upper-body powered exoskeleton, ReWalk X, and ReBoot; our ability to obtain regulatory clearances and approvals for our devices under development, including receipt of the Food and Drug Administration (the “FDA”) and international approvals; our expectations regarding reimbursement pathways and associated reimbursement rates for our upper-extremity rehabilitation product; our ability to maintain and expand Medicare, Medicare Advantage, and Veterans Affairs coverage for our products; the expected timing, design, and results of the ORMD-0801 Phase 2B clinical trial and the potential value of the POD™ platform; our expectations to achieve cash flow positive operations; the expected benefits of our strategic partnership with Oramed Pharmaceuticals Inc. (“Oramed”), including milestone-based funding availability; our transition from direct sales to a channel-partner distribution model and the anticipated benefits thereof; and our ability to grow through acquisitions and to successfully integrate acquired businesses. Such forward-looking statements are subject to risks, uncertainties, and other factors which cause actual results to differ materially from those expressed or implied by such forward-looking statements. Important factors that could cause Lifeward’s actual results to differ materially from those indicated in the forward-looking statements are more fully described in Lifeward’s periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in Lifeward’s annual and quarterly reports that Lifeward files with the SEC.

In addition, this presentation contains estimates, projections and other information concerning market, industry and other data. Lifeward obtained this data from its own internal estimates and research and from academic and industry research, publications, surveys, and studies conducted by third parties, including governmental agencies. These data involve a number of assumptions and limitations, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed in Lifeward’s filings with the SEC. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by Lifeward. While management believes such information is generally reliable, Lifeward has not independently verified any third-party information.

Forward-looking statements made in this presentation are based on a combination of facts and factors currently known to management and speak only as of the date hereof. Factors or events that could cause Lifeward’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for Lifeward to predict all of them. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements. Except as required by law, Lifeward undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

INVESTMENT THESIS

A Leading Restorative Healthcare Platform

Lifeward is a global innovator **restoring motion, independence, and quality of life**—through market-leading neurorehabilitation technology built on advanced robotics, AI, and one of the industry's most established reimbursement infrastructures.



COMMERCIAL PLATFORM: ROBOTICS FOR RESTORATIVE HEALTH

Revenue Today. Scale Tomorrow.


Robotics, AI, and reimbursement are transforming rehabilitation, with exoskeletons the fastest-growing segment. Broad reimbursement adoption—Lifeward's key competitive advantage—is what unlocks patient access and commercial scale.



THERAPEUTIC VALUE UPSIDE

Transformational Potential.

Through its strategic partnership with Oramed, Lifeward acquired the Protein Oral Delivery (POD™) platform and oral insulin candidate ORMD-0801—a significant value opportunity.



Independence, restored

MARKET OPPORTUNITY

Large and Growing Rehabilitation Markets

ROBOTICS + AI + REIMBURSEMENT ARE ACCELERATING ADOPTION

\$17B¹

Rehabilitation Equipment Market

\$27B by 2030 · 8% CAGR

\$598M²

Rehabilitation Robotics Market

\$1B by 2030 · 15% CAGR

Lifeward is uniquely positioned to capture this growth.

Established reimbursement infrastructure is a competitive moat.

Distribution channels ready to integrate and launch numerous additional devices under development serving specific rehab needs.

MILLIONS OF PATIENTS IN NEED

- Spinal Cord Injury
- Stroke
- Neuro-Rehab
- Traumatic Brain Injury
- Multiple Sclerosis
- Parkinson's Disease
- Orthopedics
- Joint Replacement
- Musculoskeletal Disorders

One commercialization platform. Built to scale.

BY THE NUMBERS

The Opportunity

GROWING REACH

37+

Countries

40+

Distributors

7000+

Units deployed

REIMBURSEMENT MOAT IN PLACE

~46%

of Medicare Advantage enrollees have coverage access

Top 3

Medicare Advantage insurers in U.S., 16M lives covered

10+ years

To build moat

OPERATING FOUNDATION

\$21.8M

LTM revenue
(as of June 30, 2026)

+16%

Revenue growth
Q2 2026 vs Q2 2025

\$11M

Cash MRQ
(as of June 30, 2026)

MULTIPLE GROWTH DRIVERS

4

Pipeline of products in development

\$24B

Future TAM

Channels

Scaling now

Growth Portfolio Set to Scale

One Platform with Multiple Device Development Programs

CURRENT PORTFOLIO

Multiple revenue engines

- ReWalk (spinal cord injury mobility)
- AlterG (anti-gravity rehab)
- Upper-body powered exoskeleton (stroke)

Three indication areas. Portfolio resilience is structural.

INTERNAL INNOVATION

Pipeline + owned IP

(Dates represent anticipated commercial launch following FDA clearance)

- StrideSense (2027)
- Upper-body exoskeleton (2028)
- ReWalk X (2029)
- ReBoot (2030+)
- Additional owned IP

Additional IP held for activation.

ACQUISITIONS

Aggregation readiness

- Fragmented market
- No scaled incumbents
- Positioned to aggregate complementary rehabilitation technologies through an established commercial and operational platform.

Active focus: execute the internal pipeline. Aggregate opportunistically when targets emerge.

PARTNERSHIP UPSIDE

Oratech Pharmaceuticals Ltd. acquired from Oramed

- Oral protein delivery platform
- Phase 2B oral insulin study pre-funded by Oramed
- Program only requires management's oversight

Strategy stands on its own; POD™ is "optional gas for the engine."

Growing portfolio with established reimbursement and distribution channels for scale



ReWalk users together in the field — independence, side by side



ReWalk in daily community use — Germany

PRODUCT · REWALK

1st FDA-Cleared Powered Exoskeleton with Medicare Coverage

LIFEWARD CREATED THE POWERED EXOSKELETON CATEGORY

Clinical Evidence

76%

ambulated without assistance

Miller et al. 2016 — 14 studies, 111 patients; no serious AEs*
*across powered exoskeletons including ReWalk

3.3 METs

Metabolic equivalent of task (MET)
sustainable — hours, not meters

Regulatory & Reimbursement

FDA 2014

HCPSC 2020

Fee Sched. 2024

~46% Medicare
Advantage

VA SOP 2015

Market & Deployment

300,000+

Americans living with spinal cord injury (SCI)¹

18,000

new SCI injuries annually¹

37+

countries with active deployment

1,000+

units in field

The only exoskeleton indicated for use on stairs.

ReWalk X (2029): AI-driven, faster training, broader SCI/MS reach**

The Problem ReWalk Solves

The Patient

- Individuals with spinal cord injury and neurological conditions who cannot walk independently.
- Recovery of locomotion is their consistently stated top priority.¹
- 300,000+ Americans live with SCI. 18,000 new injuries annually.²

Why Current Options Fail

- Traditional orthotic devices require unsustainable metabolic effort. Patients walk only 20–50 meters before stopping due to fatigue.³
- <5% of complete SCI patients can ambulate without physical assistance using traditional devices.⁴

What ReWalk Changes

- 76% ambulated without physical assistance after training.
- 3.3 METs — sustainable for hours, not meters.
- No serious adverse events.
- 14 studies, 111 patients*⁴

Patient Centered Delivery

1. Ditunno et al. (2008). Spinal Cord, 46(7), 500–506. <https://pubmed.ncbi.nlm.nih.gov/18209742/>

2. NSCISC (2024). SCI Facts and Figures. Univ. of Alabama at Birmingham. <https://msktc.org/sites/default/files/Facts-and-Figures-2024-Eng-508.pdf>

3. Sykes et al. (1995). Arch. Phys. Med. Rehabil., 76(8), 779–783. [https://www.archives-pmr.org/article/S0003-9993\(95\)80534-6/abstract](https://www.archives-pmr.org/article/S0003-9993(95)80534-6/abstract)

4. Miller et al. (2016). Medical Devices: Evidence and Research, 9, 455–466. *across powered exoskeletons including ReWalk <https://www.dovepress.com/clinical-effectiveness-and-safety-of-powered-exoskeleton-assisted-walk-peer-reviewed-fulltext-article-MDER>



AlterG product line — NEO, PRO, and NEO+

PRODUCT · ALTERG

NASA Anti-Gravity Rehabilitation

Technology

- NASA-derived Differential Air Pressure (DAP) technology reduces the effects of gravity to enable users to move with calibrated support and reduced pain.
- The only system that accurately assesses and calibrates body weight up to 100x/second in 1% increments.

Market & Deployment

- Existing installed base across rehab, sports, and military settings
- Established Durable Medical Equipment (DME) channel · capital equipment + service model

Platform Extensions in Development

StrideSense (2027*)

Cloud-connected gait analysis + gamification
Pro as medical device — expands market into clinical settings

Senior Care Variant

New market segment; concept stage

Upper-Extremity Rehabilitation Platform Extension

Product Capability

1

Multi-joint powered arm with individual finger control in development. AI intent recognition; modular hand in development, subject to FDA clearance.

Reimbursement Pathway

2

CMS L8702 established for upper-extremity orthotic at ~\$60–65K rate. Supports reimbursement opportunity.

Market Opportunity


3

Stroke: ~4M survivors with upper limb weakness, ~400K new cases per year^{1, 2}; Myomo, which has a comparable device platform, reported \$41M in revenue³.

Launch

4

Anticipated March 2028* (US) · September 2028* (EU). Target: 300–400 units/year.



Upper body powered exoskeleton with integrated AI, designed for individuals with upper-limb mobility limitations

1. 7.8 M adults with stroke <https://www.cdc.gov/nchs/fastats/stroke.htm>



2. 48-57% of whom have upper limb weakness <https://pmc.ncbi.nlm.nih.gov/articles/PMC8442135/>

3. <https://www.sec.gov/Archives/edgar/data/1369290/000119312526098531/myo-20251231.htm>

GO-TO-MARKET

Distribution: Far-Reaching Access Where Patients Need It Most

Working with the largest home medical equipment (HME) / durable medical equipment (DME) providers in the U.S.



Lifeward is transitioning from direct sales to a capital-efficient channel-partner distribution model

Faster Growth · Reduced OpEx · Accelerated Cash Collection (wholesale B2B terms)

REIMBURSEMENT

Reimbursement Moat: Code + Coverage + Payment

A decade in the making; structurally defensible

CODE

K1007

HCPCS code (2020)

Billing infrastructure established

COVERAGE

~46%

of MA enrollees

Brace Benefit (2024) · MA approvals (2025) · VA SOP (2015)

PAYMENT

\$95,081

established rate

Medicare Fee Schedule (2026) · Payment predictability




ReWalk reimbursement is a model for rolling out a growing portfolio of rehab equipment

Accessible to Patients · Supported by Payers

Devices Under Development

Pipeline & Connected Data Platform

Each device under development runs on the same infrastructure, and each addition has the potential to compound the platform’s value
(Anticipated launch dates subject to FDA clearance)



Each product runs on the commercial and reimbursement infrastructure built for ReWalk



Modular software, cloud connectivity, and AI/ML personalization: creating recurring revenue and compounding value across the portfolio. Each product in development trained on insights from the last.

FINANCIALS & PARTNERSHIP

Financial Position and Strategic Partnership

Operating metrics show commercialization underway; Oramed partnership funds execution

Financial metrics as of June 30, 2026:

\$6.6M ↑

Q2 revenue up 15% YoY

42%

Gross margin

\$10.9M

Pro forma cash position**

OpEx ↓

Operating expense trending down

STRATEGIC PARTNERSHIP STRUCTURE · ORAMED (NASDAQ: ORMP)

Oramed's Stake

- Strategic equity stake in Lifeward
- 4% royalty on ReWalk (10-year term)
- Board representation
- Performance warrants tied to milestones
- Management of POD platform

Strategic Funding

- Up to \$47M funding into Lifeward based on milestones
- \$10M of which was received in March 2026
- Acquisition of POD came with \$6.5M in development funds for ORMD-0801

July 2026 up to \$11.2M Investment

- \$5.6M received in convertible notes and warrants
- Additional \$5.6M committed based on achievement of milestones:
 - 150% increase in ReWalk sales
 - Stock trading at \$13.80 for 10 consecutive days

**Reflects \$9.4 million in cash as of June 30, 2026, plus \$1.5 million in financing proceeds received in early July 2026.

POTENTIAL TRANSFORMATIVE VALUE

Oramed POD™: Significant Upside Potential

Pre-funded · Exponential upside · Phase 2B for lead asset ORMD-0801 in development

WHAT POD REPRESENTS

- Oramed's oral protein delivery platform: potential to be a major biopharma asset
- Lifeward holds upside exposure through the partnership structure
- Pre-funded by Oramed, no Lifeward development burden or commercialization role

TRIAL HISTORY AND FORWARD PATH

- Phase 3 US trial did not meet primary endpoint
- Phase 3 China trial succeeded with modified protocol
- Subgroup analysis from US trial is the basis for upcoming Phase 2B study

TRANSFORMATIONAL VALUE

- Focus: Operational focus and investment thesis is the commercial rehab platform. POD is independent with development overseen by Oramed.
- Upside: Exposure to the oral insulin market if ORMD-0801 receives regulatory approval, plus POD's larger oral protein biologic delivery platform.

Embedded high-value asset has potential to trigger substantial returns

INVESTMENT SUMMARY

Why Now

Coverage exists. Infrastructure is built.

1

Robotics & AI transforming rehabilitation market

Lifeward is an early leader, with infrastructure built, in a \$17B rehab equipment market where robotics-powered systems is the fastest growing segment.

2

Expanding distribution channels

Increasing patient access, accelerating commercial expansion and revenue engine with capital-efficient model.

3

Reimbursement wins converting into broader adoption

A decade of category-creation work is complete. Code + Coverage + Payment trifecta established. ~46% of Medicare Advantage enrollees.

4

Platform extension underway with new products in development

Upper-body powered exoskeleton under development for upper-extremity >10x bigger addressable market compared to SCI.

Based on 300K SCI patients and ~4M stroke survivors with upper limb weakness in the U.S. This is directional, proxy-based market sizing, not a bottom up validated total addressable market size.

5

On path to cash-flow positive operations

Supported by operating leverage and capital-efficient distribution channel model.

6

Operating model rebuilt for execution

Business model built for reimbursement-driven commercialization.

Lifeward is at the leverage point — Build it. Sell it. Scale it.

Restoring motion, dignity, and independence for the people whose lives depend on it.



NASDAQ: LFWD

Thank You

Restoring motion, dignity, and independence for the people whose lives depend on it.

We welcome your questions and discussion.

Investor Presentation · September 2026

